204 results
Page 2 of 11
8-K
EX-99.1
5juo 635f8s
6 Apr 23
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
6:35am
8-K
EX-99.1
57yca6mdrp4hf77i hd
28 Dec 22
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
4:40pm
8-K
EX-99.1
ub5x utn2r6qg18meg
14 Nov 22
ImmunoGen Announces FDA Accelerated Approval of ELAHEREā¢ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
5:23pm
8-K
EX-99.1
iphmr 8h3513n7
4 Nov 22
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
6:41am
8-K
EX-99.1
msi9t fnl3y
1 Nov 22
ImmunoGen Announces Departure of Chief Commercial Officer
9:09am
8-K
EX-99.1
rai5oqu1q2xozy63g9
31 Aug 22
ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
6:40am
8-K
EX-99.1
m7rvs4nn21a0yey38bjm
29 Jul 22
ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results
6:41am
8-K
EX-99.1
wd4yhffd4itrawnrp8bp
23 May 22
Regulation FD Disclosure
6:40am
8-K
EX-99.1
i887ngo06 d1caxj
6 May 22
ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results
6:41am
8-K
EX-99.1
0jvaum
25 Feb 22
ImmunoGen Reports Recent Progress and 2021 Financial Results
6:47am
8-K
EX-99.1
l4ss 6a22q
16 Feb 22
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
4:53pm
8-K
EX-1.1
niq17x
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm